Skip to main content

Study Looks at Treatment Patterns for Alopecia Areata

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Sept. 20, 2023 -- For patients with alopecia areata (AA), corticosteroids are the most commonly used treatment, and by one year, 71.8 percent are receiving no treatment, according to a study published online Sept. 20 in JAMA Dermatology.

Hemin Lee, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues conducted a retrospective cohort study involving 45,483 individuals to review treatment patterns for adults newly treated for AA between Oct. 15, 2015, and Feb. 28, 2020.

The researchers found that 66.4 percent of the participants received at least one AA treatment during the year of follow-up. The most common treatments were intralesional, topical, intramuscular, and oral corticosteroids (41.8, 40.9, 38.1, and 20.6 percent, respectively). Patients with versus those without alopecia totalis and alopecia universalis had a lower frequency of intralesional steroid use (11.1 versus 44.1 percent) and higher frequency of topical corticosteroid use (25.4 versus 42.1 percent). On the day of diagnosis, 47.2 percent of patients received no treatment. Overall, 71.8 percent of patients were not receiving any treatment by 12 months.

"The most common treatments in this cohort were intralesional or topical corticosteroids, and there was a dynamic change in treatment over the course of a year, culminating with no prescription therapy for most patients," the authors write. "Additional studies are needed to understand the reasons for treatment absence after one year of follow-up."

Two authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Read this next

Implantable Continuous Flow Device Feasible for Small Children With Severe Systolic Heart Failure

FRIDAY, May 10, 2024 -- The Jarvik 2015 left ventricular assist device (LVAD) seems promising as an implantable continuous flow device for small children with severe systolic...

Clinical Practice Guideline Developed for Age-Related Hearing Loss

FRIDAY, May 10, 2024 -- In a clinical practice guideline issued by the American Academy of Otolaryngology-Head and Neck Surgery Foundation and published online April 30 in...

Large Language Models Fall Short in Breast Imaging Classification

FRIDAY, May 10, 2024 -- Large language models (LLMs) appear to fall short in classification of breast imaging, which can have a negative impact on clinical management, according...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.